Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens

Annals of the New York Academy of Sciences

Volumn 804, Issue , 1996, Pages 554-572

  Williams, Gary M ^a   Perrone, Carmen ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CARCINOGEN; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; GEMFIBROZIL; METHYLCLOFENAPATE; NAFENOPIN; PARAFFIN; PEROXISOME PROLIFERATOR; PIRINIXIL; TIBRIC ACID; TOMELUKAST; TRICHLOROETHYLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CONFERENCE PAPER; DNA DAMAGE; LIVER CARCINOGENESIS; NONHUMAN; PEROXISOME; PRIMATE; RISK ASSESSMENT;

ANIMALIA; PRIMATES; RODENTIA;

EID: 0030451011     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb18645.x     Document Type: Conference Paper

References (69)

1. BENNETT, A. M. & G. M. WILLIAMS. 1993. Calcium as a permissive factor but not an initiation factor in DNA synthesis induction in cultured rat hepatocytes by the peroxisome proliferator ciprofibrate. Biochem. Pharmacol. 46: 2219-2227.
2. BENTLEY, P., I. CALDER, C. ELCOMBE, P. GRASSO, D. STRINGER & H. J. WIEGAND. 1993. Hepatic peroxisome proliferation in rodents and its significance for humans. Fd. Chem. Toxicol. 31: 857-907.
3. BICHET, N., D. CAHARD, G. FABRE, B. REMANDET, D. GOUY & J.-P. CANO. 1990. Toxicological studies on a benzofuran derivative. Toxicol. Appl. Pharmacol. 106: 509-517.
4. BLANE, E. F. & F. PINAROLI. 1984. Fenofibrate: Études de toxicologie animale en rapport avec les effets secondaires chez les malades. La Nouvelle Presse Médicale. 9: 3737-3746.
5. BLÜMCKE, S., W. SCHWARTZKOPFF, H. LOBECK, N. A. EDMONDSON, D. E. PRENTICE & G. F. BLANE. 1983. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis. 46: 105-116.
6. BUDROE, J. D., T. UMEMURA, K. ANGELOFF & G. M. WILLIAMS. 1992. Dose-response relationships of hepatic acyl CoA oxidase and catalase activity and liver mitogenesis induced by the peroxisome proliferator ciprofibrate in C57BL/6N and BALB/c mice. Toxicol. Appl. Pharmacol. 113: 192-198.
7. BUDROE, J. D. & G. M. WILLIAMS. 1993. Genotoxicity studies of peroxisome proliferators. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 525-568. Taylor and Francis, Ltd. London.
8. BUTTERWORTH, B. E. 1990. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat. Res. 239: 117-132.
9. CATTLEY, R. C. & J. A. POPP. 1989. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver. Cancer Res. 49: 3246-3251.
10. CATTLEY, R. C., M. KATO, J. A. POPP & K. S. VOSS. 1994. Initiator-specific promotion of hepatocarcinogenesis by WY-14,643 and clofibrate. Carcinogenesis. 15: 1763-1766.
11. CAYEN, M. N. 1985. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmac. Ther. 29: 157-204.
12. CHEN, H., C. HUANG, M. W. WILSON, L. T. LAY, L. W. ROBERTSON, C. K. CHOW & H. P. GLAUERT. 1994. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. Carcinogenesis 15: 2847-2850.
13. COHEN, S. M. & L. B. ELLWEIN. 1990. Cell proliferation in carcinogenesis. Science. 249: 1007-1011.
14. COMMISSION OF THE EUROPEAN COMMUNITIES (CEC). 1993. Commission Directive 93/67/EEC of July 1993. Official Journal of the European Communities. L 227: 9-18.
15. DE LA IGLESIA, F. A., J. E. LEWIS, R. A. BUCHANAN, E. L. MARCUS & G. MCMAHON. 1982. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gem-fibrozil treatment. Atherosclerosis. 43: 19-37.
16. DIRVEN, H. A. A. M., P. H. H. VAN DEN BROEK, M. C. E. PEETERS, J. G. P. PETERS, W. C. MENNES, B. J. BLAAUBOER, J. NOORDHOEK & F. J. JONGENEELEN. 1993. Effects of the peroxisome proliferator mono(2-ethylhexyl)phthalate in primary hepatocyte cultures derived from rat, guinea pig, rabbit and monkey. Biochem. Pharmacol. 45: 2425-2434.
17. EACHO, P. I., P. S. FOXWORTHY, W. D. JOHNSON, D. M. HOOVER & S. L. WHITE. 1986. Hepatic peroxisome changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol. Appl. Pharmacol. 83: 430-437.
18. EACHO, P. I., T. L. LANIER, P. S. FOXWORTHY & D. M. HOOVER. 1992. Effect of the peroxisome proliferator LY 171883 on hepatocellular replication in female B6C3F1 mice. Fundam. Appl. Toxicol. 18: 632-634.
19. ELCOMBE, C. R. & A. M. MITCHELL. 1986. Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEHP): Species differences and possible mechanisms. Env. Health Persp. 70: 211-219.
20. FAHIMI, H. D., E. BAUMGART, K. BEIER, J. PILL, F. HARTIG & A. VÖLKL. 1993. Ultrastructural and biochemical aspects of peroxisome proliferation and biogenesis in different mammalian species. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 373-393. Taylor and Francis, Ltd. London.
21. FOXWORTHY, P. S., S. L. WHITE, D. M. HOOVER & I. EACHO. 1990. Effect of ciprofibrate, bezafibrate and LY 171883 on peroxisomal β-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104: 386-394.
22. FRICK, H., ELO, K. HAAPA, O. P. HEINOMEN, et al. 1987. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl. J. Med. 317: 1235-1247.
23. GARIOT, P., E. BARRAT, P. DROUIN, P. GENTON, J. P. POINTEL, B. FOLIGUET, M. KOLOPP & G. DEBRY. 1987. Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism 36: 203-210.
24. GLAUERT, H. P., D. BEER, M. S. RAO, M. SCHWARTZ, Y. XU, T. L. GOLDSWORTHY, J. COLOMA & H. C. PITOT. 1986. Induction of altered hepatic foci in rats by the administration of hypolipidemic peroxisome proliferators alone or following a single dose of diethylnitrosamine. Cancer Res. 46: 4601-4606.
25. GOLDFISCHER, S. 1974. Peroxisomes in disease. J. Histochem. Cytochem. 27: 1371.
26. GRAHAM, M. J., S. A. WILSON, M. A. WINHAM, A. J. SPENCER, J. A. REES, S. L. OLD & F. W. BONNER. 1994. Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fund. Appl. Toxicol. 22: 58-64.
27. GRASSO, P. 1987. Persistent organ damage and cancer production in rats and mice. Mech. Models Toxicol. 11: 75-83.
28. GRAY, R. H. & F. A. DE LA IGLESIA. 1984. Quantitative microscopy comparison of peroxisome proliferation by the lipid-regulating agent gemfibrozil in several species. Hepatol. 4: 520-530.
29. HANEFELD, M., C. KEMMER & E. KADNER. 1983. Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46: 239-246.
30. HOLLOWAY, B. R., M. BENTLEY & J. M. THORP. 1982. Species differences in the effects of ICI 55,897 on plasma lipids and hepatic peroxisomes. Ann. N.Y. Acad. Sci. 386: 439-442.
31. HOLLOWAY, B. R., J. M. THORP, G. D. SMITH & T. J. PETERS. 1982. Analytical subcellular fractionation and enzymic analysis of liver homogenates from control and clofibrate-treated rats, mice, and monkeys with reference to the fatty acid-oxidizing enzymes. Ann. N.Y. Acad. Sci. 386: 453-454.
32. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. 1996. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Pharmaceutical Drugs. World Health Organization. International Agency for Research on Cancer. Lyon, France.
33. KLUWE, W. M. 1994. The relevance of hepatic peroxisome proliferation in rats to assessment of human carcinogenic risk for pharmaceuticals. Reg. Toxicol. Pharmacol. 20: 170-186.
34. LAKE, B. G., J. G. EVANS, T. J. B. GRAY, S. A. KÖRÖSI & C. J. NORTH. 1989. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol. Appl. Pharmacol. 99: 148-160.
35. LAKE, B. G. & D. F. V. LEWIS. 1993. Structure-activity relationships for chemically induced peroxisome proliferation in mammalian liver. In Peroxismes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 313-336. Taylor and Francis, Ltd. London.
36. LALWANI, N. D., M. K. REDDY, S. GHOSH, S. D. BARNARD, J. A. MOLELLO & J. K. REDDY. 1985. Induction of fatty acid β-oxidation and peroxisome proliferation in the liver of rhesus monkeys by DL-040, a new hypolipidemic agent. Biochem. Pharmacol. 34: 3473-3482.
37. LAZAROW, P. B. 1981. Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol. 72: 315-319.
38. LEBER, H., E. G. BUTLER, T. TANAKA, H. MARUYAMA & G. M. WILLIAMS. 1988. Induction of hepatic peroxisome proliferation by lactofen, a diphenyl ether herbicide. Toxicologist 8: 177 (abstract).
39. MAKOWSKA, J. M., F. W. BONNER & G. G. GIBSON. 1991. Comparative induction of cytochrome P450IVAI and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch. Toxicol. 65: 106-113.
40. MANNAERTS, G. P. & P. P. VAN VELDHOVEN. 1993. Metabolic role of mammalian peroxisomes. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 19-62. Taylor and Francis, Ltd. London.
41. MARSMAN, D. S., R. C. CATTLEY, J. G. CONWAY & J. A. POPP. 1988. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-2-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res. 48: 6739-6744.
42. MARUYAMA, H., T. TANAKA & G. M. WILLIAMS. 1990. Effects of the peroxisme proliferator di(2-ethylhexyl)phthalate on biochemical properties in rat liver and on carcinogen-induced liver altered foci in comparison to the promoter phenobarbital. Toxicol. Path. 18: 257-267.
43. MENNES, W. C., H. M. WORTELBOER, G. A. M. HASSING, K. VAN SANDWIJK, A. TIMMERMAN, B. P. SCHMID, U. JAHN & B. J. BLAAUBOER. 1994. Effects of clofibric and beclobric acid in rat and monkey hepatocyte primary culture: Influence on peroxisomal and mitochondrial β-oxidation and the activity of catalase, glutathione S-transferase and glutathione peroxidase. Arch. Toxicol. 68: 506-511.
44. MOCHIZUKI, Y., K. FURUKAWA & N. SAWADA. 1982. Effects of various concentrations of ethyl-alpha-p-chlorophenoxyisobutyrate (clofibrate) on diethylnitrosamine-induced hepatic tumorigenesis in the rat. Carcinogenesis (Lond.) 3: 1027-1029.
45. NUMOTO, S., H. MORI, K. FURUYA, W. G. LEVINE & G. M. WILLIAMS. 1985. Absence of a promoting or sequential syncarcinogenic effect in rat liver by the carcinogenic hypolipidemic drug nafenopin given after N-2-fluorenylacetamide. Toxicol. App. Pharmacol. 77: 76-85.
46. ORTON, T. C., H. K. ADAM, M. BENTLEY, B. HOLLOWAY & M. TUCKER. 1984. Clobuzarit: Species differences in the morphological and biochemical response of the liver following chronic administration. Toxicol. Appl. Pharmacol. 73: 138-151.
47. PRÉAT, V., M. LANS, J. DE GERLACHE, H. TAPER & M. ROBERFROID. 1986a. Comparison of the biological effects of phenobarbital and nafenopin on rat hepatocarcinogenesis. Gann 77: 629-638.
48. PRÉAT, V., J. DE GERLACHE, M. LANS, H. TAPER & M. ROBERFROID. 1986b. Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichlorethane, butylated hydroxytoluene and nafenopin on rat hepatocarcinogenesis. Carcinogenesis (Lond.) 7: 1025-1028.
49. RAO, M. S. & J. K. REDDY. 1989. The relevance of peroxisome proliferation and cell proliferation in peroxisome proliferator-induced hepatocarcinogenesis. Drug Metab. Rev. 21: 103-110.
50. REDDY, J. K., D. L. AZARNOFF & C. E. HIGNITE. 1980. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature (Lond.) 283: 397-398.
51. REDDY, J. K. & N. D. LALWANI. 1983. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Critical Rev. Toxicol. 12: 1-58.
52. REDDY, J. K., LALWANI, N. D., S. A. QURESHI, M. K. REDDY & C. M. MOEHLE. 1983. Induction of hepatic peroxisome proliferation in nonrodent species, including primates. Am. J. Pathol. 114: 171-183.
53. REDDY, J. K. & M. S. RAO. 1978. Enhancement by WY-14,643, a hepatic peroxisome proliferator, of diethylnitrosamine-initiated hepatic tumorigenesis in the rat. Br. J. Cancer 38: 537-543.
54. RHODES, C., T. C. ORTON, I. S. PRATT, P. L. BATTEN, H. BRATT, S. J. JACKSON & C. R. ELCOMBE. 1986. Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl)phthalate (DEHP) in rats and marmosets: Extrapolation of effects in rodents to man. Env. Health Persp. 65: 299-308.
55. SAUSEN, P. J., D. C. LEE, M. L. ROSE & R. C. CATTLEY. 1995. Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to mitochondrial alterations. Carcinogenesis 160(8): 1795-1801.
56. SCHULZ, C. O. 1989. Assessing human health risks from exposure to di(2-ethylhexyl)-phthalate (DEHP) and related phthalates: Scientific issues. Drug Metab. Rev. 21: 111-120.
57. SHORT, R. D., E. C. ROBINSON, A. W. LINGTON & A. E. CHIN. 1987. Metabolic and peroxisome proliferator studies with di(2-ethylhexyl)phthalate in rats and monkeys. Toxicol. Indus. Health 3: 185-195.
58. SMALL, G. M., K. BURDETT & M. J. CONNOCK. 1985. A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochemistry 227: 205-210.
59. STOTT, W. T. & N. C. HAWKINS. 1993. Risk assessment of chemicals inducing peroxisome proliferation. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 695-721. Taylor and Francis, Ltd. London.
60. TAKAGI, A., K. SAI, T. UMEMURA, R. HASEGAWA & Y. KUROKAWA. 1993. Production of 8-hydroxydeoxyguanosine in rodent liver by the administration of peroxisome proliferators. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 569-594. Taylor and Francis, Ltd. London.
61. TAMURA, H., T. IJDA, T. WATANABE & T. SUGA. 1991. Lack of induction of hepatic DNA damage on long-term administration of peroxisome proliferators in male F-344 rats. Toxicol. 69: 55-62.
62. TUCKER, M. J. & T. C. ORTON. 1993. Toxicological studies in primates with three fibrates. In Peroxisomes: Biology and Importance in Toxicology and Medicine. G. Gibson & B. Lake, Eds.: 425-463. Taylor and Francis, Ltd. London.
63. TURNBULL, D. & J. V. RODRICKS. 1985. Assessment of possible carcinogenic risk to humans resulting from exposure to di(2-ethylhexyl)phthalate (DEHP). J. Am. Coll. Toxicol. 4: 111-145.
64. WADA, N., D. S. MARSMAN & J. A. POPP. 1992. Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication. Fund. Appl. Toxicol. 18: 149-154.
65. WARD, J. M., J. M. RICE, D. CREASIA, P. LYNCH & C. RIGGS. 1983. Dissimilar patterns of promotion by di(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice. Carcinogenesis (Lond.) 4: 1021-1029.
66. WILLIAMS, G. M. 1984. Modulation of chemical carcinogenesis by xenobiotics. Fund. Appl. Toxicol. 4: 325-344.
67. WILLIAMS, G. M. 1990. Epigenetic mechanisms of liver tumor promotion. In Mouse Liver Carcinogenesis. D. E. Stevenson, R. M. McClain, J. A. Popp, T. J. Slaga, J. M. Ward & H. C. Pitot, Eds.: 31-145. Alan R. Liss, Inc. New York.
68. WILLIAMS, G. M. 1992. DNA reactive and epigenetic carcinogens. Exp. Toxicol. Path. 44: 457-464.
69. WILLIAMS, G. M., H. MARUYAMA & T. TANAKA. 1987. Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis. Carcinogenesis 8: 875-880.